ES2535258T3 - Proteína de unión al antígeno de Goodpasture y su detección - Google Patents

Proteína de unión al antígeno de Goodpasture y su detección Download PDF

Info

Publication number
ES2535258T3
ES2535258T3 ES09777309.7T ES09777309T ES2535258T3 ES 2535258 T3 ES2535258 T3 ES 2535258T3 ES 09777309 T ES09777309 T ES 09777309T ES 2535258 T3 ES2535258 T3 ES 2535258T3
Authority
ES
Spain
Prior art keywords
gpbp
kda
antibodies
native
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09777309.7T
Other languages
English (en)
Spanish (es)
Inventor
Fernando Revert
Juan Saus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FibroStatin SL
Original Assignee
FibroStatin SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FibroStatin SL filed Critical FibroStatin SL
Application granted granted Critical
Publication of ES2535258T3 publication Critical patent/ES2535258T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11009—Goodpasture-antigen-binding protein kinase (2.7.11.9)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
ES09777309.7T 2008-07-22 2009-07-20 Proteína de unión al antígeno de Goodpasture y su detección Active ES2535258T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82741P 1998-04-23
US8274108P 2008-07-22 2008-07-22
US8521108P 2008-07-31 2008-07-31
US85211P 2008-07-31
PCT/EP2009/005258 WO2010009856A2 (en) 2008-07-22 2009-07-20 Goodpasture antigen binding protein and its detection

Publications (1)

Publication Number Publication Date
ES2535258T3 true ES2535258T3 (es) 2015-05-07

Family

ID=41202276

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09777309.7T Active ES2535258T3 (es) 2008-07-22 2009-07-20 Proteína de unión al antígeno de Goodpasture y su detección

Country Status (6)

Country Link
US (3) US7935492B2 (enExample)
EP (1) EP2318039B1 (enExample)
JP (1) JP5654989B2 (enExample)
CN (1) CN102300583A (enExample)
ES (1) ES2535258T3 (enExample)
WO (1) WO2010009856A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5654989B2 (ja) * 2008-07-22 2015-01-14 フィブロスタチン ソシエダ リミターダＦｉｂｒｏｓｔａｔｉｎ，Ｓｏｃｉｅｄａｄ Ｌｉｍｉｔａｄａ グッドパスチャー抗原結合タンパク質およびその検出
CN105148269A (zh) * 2011-02-21 2015-12-16 菲布他丁有限合伙公司 治疗和诊断疾病的方法
JP2015524385A (ja) 2012-07-02 2015-08-24 フィブロスタティン，エス．エル． Ｇｐｂｐ−１阻害およびその治療的使用
CN105723224A (zh) * 2013-09-27 2016-06-29 菲布他丁有限合伙公司 古德帕斯丘抗原结合蛋白检测和抑制以及其在糖尿病中的应用
WO2016107906A1 (en) 2014-12-31 2016-07-07 Fibrostatin, S.L. Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition
CN107966569A (zh) * 2017-12-27 2018-04-27 湖北普罗金科技有限公司 一种具有冷却通风功能的蛋白质鉴定工作台
WO2025032091A1 (en) * 2023-08-08 2025-02-13 F. Hoffmann-La Roche Ag Peptide biomarker for neurological disease, in particular motor neuron disease
CN119322175A (zh) * 2024-10-18 2025-01-17 武汉塞力斯生物技术有限公司 一种血管炎抗体联检试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5625048A (en) * 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US6124128A (en) * 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
US6579969B1 (en) * 1999-02-24 2003-06-17 Juan Saus Goodpasture antigen binding protein
US6881547B1 (en) 2001-01-31 2005-04-19 Juan Saus Methods and reagents for treating autoimmune disorders
US7147855B2 (en) * 2001-12-07 2006-12-12 Juan Saus GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
WO2004070025A2 (en) 2003-02-05 2004-08-19 Juan Saus Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
JP5654989B2 (ja) * 2008-07-22 2015-01-14 フィブロスタチン ソシエダ リミターダＦｉｂｒｏｓｔａｔｉｎ，Ｓｏｃｉｅｄａｄ Ｌｉｍｉｔａｄａ グッドパスチャー抗原結合タンパク質およびその検出

Also Published As

Publication number Publication date
EP2318039B1 (en) 2015-04-08
US20110189707A1 (en) 2011-08-04
JP2011528559A (ja) 2011-11-24
US20100021935A1 (en) 2010-01-28
CN102300583A (zh) 2011-12-28
JP5654989B2 (ja) 2015-01-14
WO2010009856A2 (en) 2010-01-28
US20150064716A1 (en) 2015-03-05
EP2318039A2 (en) 2011-05-11
US7935492B2 (en) 2011-05-03
WO2010009856A3 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
US20150064716A1 (en) Goodpasture Antigen Binding Protein and Its Detection
KR102240417B1 (ko) 항-트랜스티레틴 인간 항체
CN106574258A (zh) 抗‑运甲状腺素蛋白人源化抗体
US20240076361A1 (en) Anti-pt217 tau antibody
US20240368257A1 (en) Filamin a binding proteins and uses thereof
US9790503B2 (en) VHZ for diagnosis and treatment of cancer
EP3917571A1 (en) Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
CN113508300A (zh) 用于人类阿尔茨海默病的新型生物标记物
US20220363738A1 (en) Method
US11629183B2 (en) Monoclonal antibodies targeting microtubule-binding domain of tau protein and methods of detecting tau protein in vivo
EP3441769B1 (en) Phosphorylated ubiquitin protein
US20190002543A1 (en) Inflammatory Disease Treatment Composition Including Anti-Myosin Regulatory Light-Chain Polypeptide Antibody
WO2021225781A2 (en) Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
US11981729B2 (en) Method
WO2020100779A1 (ja) ｐＳｅｒ４６－ＭＡＲＣＫＳに特異的に結合するモノクローナル抗体